Conventional heart failure therapy in cardiac ATTR amyloidosis.
Adam IoannouPaolo MassaRishi K PatelYousuf RazviAldostefano PorcariMuhammad U RaufAnita JiangGiacomo CabrasStefano FilisettiRoos E BolhuisFrancesco BanderaLucia VenneriAna Martinez-NaharroSteven LawTushar KotechaRuta VirsinskaiteDaniel S KnightMichele EmdinAviva PetrieHelen LachmannAshutosh WechelakarMark PetrieAlun D HughesNick FreemantlePhilip N HawkinsCarol WhelanJohn Jv McMurrayJulian David GillmoreMarianna FontanaPublished in: European heart journal (2023)
Conventional HF medications are currently not widely prescribed in ATTR-CA, and those that received medication had more severe cardiac disease. Beta-blockers and ACEi/ARBs were often discontinued, but low-dose beta-blockers were associated with reduced risk of mortality in patients with a LVEF ≤40%. In contrast, MRAs were rarely discontinued and were associated with reduced risk of mortality in the overall population; but these findings require confirmation in prospective randomized controlled trials.
Keyphrases
- low dose
- heart failure
- left ventricular
- cardiovascular events
- randomized controlled trial
- angiotensin converting enzyme
- risk factors
- magnetic resonance
- high dose
- early onset
- type diabetes
- emergency department
- atrial fibrillation
- cardiovascular disease
- clinical trial
- magnetic resonance imaging
- study protocol
- coronary artery disease
- cell therapy
- bone marrow
- contrast enhanced
- drug induced